Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference

September 5, 2013 08:37 (CEST)

LUND, Sweden, Sept. 5, 2013 (GLOBE NEWSWIRE) --

Lund, Sweden, September 5, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Rodman & Renshaw Annual Global Investment Conference
held September 8-10, 2013 in New York, USA. During the presentation, an update
regarding Active Biotech's development programs will be provided.

The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical, the Phase III prostate cancer project
tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's
novel concept for tumor therapy of primarily renal cell cancer. Also, the
project 57-57 (paquinimod) and the pre-clinical ISI project will be

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to -

The presentation will take place on September 9, at 3:40 p.m. EDT (Eastern
Daylight Time) / 21:40 Central European Summer Time.

For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod is in clinical development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound paquinimod (57-57) for systemic sclerosis. Please visit for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 8:30 a.m. CET on September 5, 2013.

Active Biotech to Present at  the Rodman & Renshaw Annual Global Inves: